On AAML1831 (NCT04293562) (Table 7), MECOM-RPN1 and MECOM-RUNX1 fusions are classified as unfavorable prognostic markers, and AML patients harboring these fusions are treated per the high-risk arm (two induction cycles and one intensification chemotherapy cycle followed by allo-HSCT). This evidence concerns the gene RUNX1 and acute myeloid leukemia.